Chapter 11: HPV vaccines: Commercial Research & Development

Breitburd, 1995, Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, J Virol, 69, 3959, 10.1128/JVI.69.6.3959-3963.1995 Suzich, 1995, Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas, Proc Natl Acad Sci U S A, 92, 11553, 10.1073/pnas.92.25.11553 Kirnbauer, 1996, Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization, Virology, 219, 37, 10.1006/viro.1996.0220 Jansen, 1995, Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation, Vaccine, 13, 1509, 10.1016/0264-410X(95)00103-8 Kreider, 1987, Laboratory production in vivo of infectious human papillomavirus type 11, J Virol, 61, 590, 10.1128/JVI.61.2.590-593.1987 Stanley, 2006, Immune responses to human papillomavirus, Vaccine, 24, S16, 10.1016/j.vaccine.2005.09.002 Stern, 2005, Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination, J Clin Virol, 32, S72, 10.1016/j.jcv.2004.12.005 Boland, 2004, Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04, Vaccine, 23, 316, 10.1016/j.vaccine.2004.06.006 Ruiz, 2005, Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant, J Immune Ther Vaccines, 3, 2, 10.1186/1476-8518-3-2 Roden, 1996, In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype, J Virol, 70, 5875, 10.1128/JVI.70.9.5875-5883.1996 Lowe, 1997, Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast, J Infect Dis, 176, 1141, 10.1086/514105 Bonnez, 2005, The HPV xenograft severe combined immunodeficiency mouse model, Methods Mol Med, 119, 203 Smith, 1995, Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro, J Invest Dermatol, 105, 438, 10.1111/1523-1747.ep12321173 McClements, 2001, A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1, Virology, 289, 262, 10.1006/viro.2001.1146 van Doorn, 2002, Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay, J Clin Microbiol, 40, 979, 10.1128/JCM.40.3.979-983.2002 Brown, 2004, Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine, Vaccine, 22, 2936, 10.1016/j.vaccine.2003.11.059 Pastrana, 2004, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18, Virology, 321, 205, 10.1016/j.virol.2003.12.027 Carter, 1994, Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts, Virology, 199, 284, 10.1006/viro.1994.1126 Dias, 2005, Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18, Clin Diagn Lab Immunol, 12, 959, 10.1128/CDLI.12.8.959-969.2005